Cipla Medpro delists from JSE

The South-African based Cipla Medpro has joined hands with Cipla India as the two pharmaceutical companies completed a deal valued at $500m (R5 billion), a significant foreign direct investment into the country that will not only benefit all stakeholders, but also promote opportunities both locally and throughout Africa, says Cipla India CEO Subhanu Saxena, who was recently in South Africa to complete proceedings at the company.

Ascendis Health raises R 850 million and acquires Solal Technologies and Marltons

Ascendis Health (Pty) Limited, the health and care products company, today announced the acquisition of Solal Technolgies (Solal) and the investment into a majority stake in Marltons for approximately R 300 million.  Ascendis simultaneously raised R 850 million of capital, with a R500m ‘bridge to bond’ loan from Standard Bank and Sanlam, to consolidate its debt into a single facility and a further R 350 million equity from Ascendis’ shareholders.

Mediscor Medicines Review - media release

Pharmaceutical benefit management company Mediscor PBM today announced that medicine expenditure has continued the downward trend first exhibited in 2011, when spend decreased by 5.1%. Commenting on the findings of the 2012 Mediscor Medicines Review (MMR), Christo Rademan, Managing Director of Mediscor PBM, said medicine expenditure has again reflected a decrease, albeit by a slight 0.6%.